Comprehensive Analysis of the Curosurf (Poractant Alfa) Market 2025-2034: Growth Rates, Trends, and Future Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the curosurf (poractant alfa) market grown over the years?
The market size for curosurf (poractant alfa) has seen a HCAGR of XX in the past few years. The projection is that it will escalate from an impressive $XX million in 2024 to a promising $XX million in 2025, boasting a compound annual growth rate (CAGR) of XX%. This substantial growth over the historical period is a result of a soaring demand for cutting-edge medical solutions, an upturn in the requirement for synthetic surfactants used in sanitary products, heightened awareness of and access to healthcare, growing preference for easy cleanliness consequently driving sales of synthetic surfactant, and an overall increase in health consciousness.
What Is the forecasted market size and growth rate for the curosurf (poractant alfa) market?
The market size of curosurf (poractant alfa) is projected to grow at a compound annual growth rate (CAGR) of XX% over the next few years, increasing to $XX million by 2029. This growth in the forecast period is ascribed to the increasing incidence of premature births, the widening application of synthetic surfactants in agrochemicals, the escalating occurrence of chronic respiratory diseases, larger healthcare spending, and a growing inclination towards respiratory infection treatments. The major trends emerging in this forecast period encompass the initiation of microdosing strategies, the incorporation of surfactant therapy, the rise in adoption of biologic and immunomodulatory therapies, a drift towards sustainable and green surfactants, and an emphasis on neonatal and pediatric care.
Get your curosurf (poractant alfa) market report here!
https://www.thebusinessresearchcompany.com/report/curosurf-poractant-alfa-global-market-report-
What are the major factors driving growth in the curosurf (poractant alfa) market?
The anticipated surge in the Curosurf (poractant alfa) market is linked to the rising frequency of respiratory disorders. These common complications encompass conditions like COPD, asthma, and lung cancer, which hamper breathing and impair lung functions. The escalating cases of respiratory disorders are attributable to rampant air pollution aggravating problems like asthma and an increasingly aging population prone to age-related ailments like COPD. Poractant alfa is commonly used to alleviate symptoms of neonatal respiratory distress syndrome by enhancing lung function and aiding breathing in premature infants via an endotracheal tube. As per the National Asthma Council, an Australian non-profit entity, in November 2023, in Australia, 467 deaths related to asthma were recorded in 2022, including 299 females and 168 males. This data indicates an upward shift from 355 fatalities documented in 2021. Hence, the escalating rates of respiratory disorders are fuelling the expansion of the Curosurf (poractant alfa) market. The soaring cases of premature births are likely to steer the growth of the Curosurf (poractant alfa) market. Premature births define the birth of infants prior to completion of 37 weeks of gestation in a typically 40-week full-term pregnancy. The uptick in premature births is related to an increase in the maternal age and amplified usage of assisted reproductive technologies, resulting often in multiple pregnancies. Poractant alfa is utilized to manage premature infants battling respiratory distress syndrome by minimizing lung surface tension, facilitating the lungs to remain open and enhancing oxygen exchange. As per data by the Office for National Statistics, a government department in the UK, in May 2024, in 2022, the premature live birth rate in England and Wales witnessed a rise to 7.9%, from 7.5% in 2021. This thereby implies that the rising occurrence of premature births is propelling the surge in Curosurf (poractant alfa) market.
What key areas define the segmentation of the global curosurf (poractant alfa) Market?
The curosurf (poractant alfa)market covered in this report is segmented –
1) By Type: Natural Poractant Alfa; Synthetic Poractant Alfa
2) By Sales Channel: Direct Sales; Distribution Channels; Online Marketplace
3) By Application: Pulmonary Edema; Respiratory Distress Syndrome; Other Respiratory Disorders
4) By End User: Hospitals; Clinics; Ambulance Services
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19893&type=smp
What are the top market players propelling the growth of the curosurf (poractant alfa) industry?
Major companies operating in the curosurf (poractant alfa) market include Chiesi Farmaceutici S.p.A
What are the key trends shaping the future of the curosurf (poractant alfa) market?
The curosurf (poractant alfa) market’s principal trend is gearing towards the creation of innovative solutions such as groundbreaking inhaled gene therapy addressing unserved demands in respiratory diseases. This sophisticated strategy refers to the application of therapeutic genes directly to the lungs via inhalation, typically done through aerosolized particles or nanoparticles. For instance, in November 2024, AlveoGene, a UK based firm developing gene therapies, obtained Rare Pediatric Disease Designation (RPDD) from the FDA for AVG-002. This is an original inhaled gene therapy targeting the deadly neonatal surfactant protein B (SP-B) deficiency – a severe genetic disorder leading to respiratory collapse in newborns. Currently, solutions for SP-B deficiency caused by mutations in the SFTPB gene, are scarce with lung transplantation being the principal treatment. AVG-002 uses AlveoGene’s InGenuity platform to deliver a working SP-B gene directly to the lungs, showing promising potential in preclinical trials.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19893
What regions are dominating the curosurf (poractant alfa) market growth?
North America was the largest region in the curosurf (poractant alfa) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the curosurf (poractant alfa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Anti-Vascular Endothelial Growth Factor Therapeutics Global Market Report 2025
Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2025
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
